These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results Terminated 2004-004129-89 Potentiation of procedural motor learning by pharmacological neuromodulation and brain stimulation 2013-01-16 due-trials
Reported results Terminated 2005-001113-18 Beeinflussung assoziativen Lernens und motorischer Fähigkeiten durch G-CSF und EPO 2008-09-17 due-trials
Reported results 2005-005638-10 Evaluation of the antipruritic effect of Elidel (pimecrolimus) in non-atopic pruritic disease 2009-12-04 due-trials
Reported results 2005-005966-35 A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib added to standard primary therapy in elderly patients with newly diagnosed AML 2009-07-07 due-trials
Reported results 2006-000821-74 A randomized. double-blind, placebo-controlled, phase III trial for the efficacy of Traumeel S in the prevention and treatment of chemotherapie-induced Mucositis in Patients undergoing allogeneic stem... 2007-12-20 due-trials
Reported results Terminated 2006-002767-41 Kardiale Innervation bei genetischen Arrhythmiemodellen in Menschund Maus 2014-07-31 due-trials
Reported results 2006-005854-61 Adjunctive antimicrobial therapy of periodontitis: Long-term effects on disease progression and oral microbiological colonization 2011-12-31 due-trials
Exempt, with results Terminated 2006-005970-26 A Randomized (Phase II), Double-blind, Multicenter Phase I/II trial of Pemetrexed, Carboplatin plus or minus Sorafenib in the First-line Treatment of Patients with Stage IIIb or IV Non-Small Cell Lung... 2010-01-21 not-yet-due
Not reported Terminated 2007-000259-33 Perioperative protective effects of lidocaine - clinical study on the route and timing of administration 2014-03-17 due-trials
Reported results 2008-001371-30 Anxiolytic effects of single-dose quetiapine XR administration on clinical symptoms and amygdala activation during exposure in patients with simple phobia 2011-03-02 due-trials
Reported results 2008-003658-13 EWING 2008 2019-06-30 due-trials
Reported results 2008-004583-40 A randomized, multi-center phase II trial to assess the efficay of 5-azacytidine added to standard primery therapy in elderly patients with newly diagnosed AML. 2012-12-08 due-trials
Reported results 2009-011454-17 Etude pharmacocinétique de la doxorubicine en fonction de l'âge chez des enfants atteints de tumeurs ou leucémies. 2013-05-29 due-trials
Reported results Terminated 2009-017595-25 Balanced 6 % HES 130/0.4 vs. balanced crystalloid-based infusion in patients undergoing colorectal surgery Balancierte 6% HES 130/0.4-Lösung vs. balancierte Kristalloid-Lösung bei Patienten mit kol... 2015-03-23 due-trials
Listed as ongoing, but also has a completion date and reported results 2009-018072-33 Prospective Trial for the diagnosis and treatment of children, adolescents and young adults with Intracranial Germ Cell Tumours 2020-06-30 bad-data
Not reported 2010-019345-26 Immunmodulatory effects of local anesthetics on neutrophils during sepsis 2013-02-25 due-trials
Reported results 2010-023645-29 Efficacy and safety of fumaric acid esters in the treatment of patients with cutaneous lupus erythematosus: A monocentre, open-label, prospective pilot study 2014-02-12 due-trials
Reported results Terminated 2010-024115-14 Preoperative Intravenous Ferric Carboxymaltose (Ferinject) in Patients with Orthopaedic Surgery and High Risk of Blood Loss Intravenöse Gabe von Eisen-Carboxymaltose (Ferinject) zur präoperativen T... 2013-04-09 due-trials
Reported results Terminated 2010-024131-16 Efficacy and Safety of oral Alitretinoin (Toctino®) in the Treatment of Patients with Cutaneous Lupus Erythematosus: A Multicentre, Open-Label, Prospective Pilot Study 2014-04-30 due-trials
Exempt, with results 2011-001086-41 A randomized, placebo-controlled, multi-center phase I/II trial to assess the safety and efficacy of nintedanib (BIBF 1120) added to low-dose cytarabine in elderly patients with AML unfit for an inten... 2021-07-27 not-yet-due
Reported results 2012-000108-13 A phase II multicenter trial with Rivaroxaban in the treatment of livedoid vasculopathy assessing the pain on a visual analog scale (VAS) 2014-09-11 due-trials
Reported results 2013-001601-85 Aprepitant in histamine-refractory chronic pruritus: a multicenter, randomized, double-blind, placebo-controlled, cross-over, phase II trial 2016-01-04 due-trials
Not reported 2013-003234-32 Pathological changes in the myocardial microvasculature - a MR-based quantification Pathologische Veränderungen der myokardialen Mikrovaskulatur – eine MR-basierte Quantifizierung 2018-12-31 due-trials
Other 2013-003253-21 B-NHL 2013 - Treatment protocol of the NHL-BFM and the NOPHO study groups for mature aggressive B-cell lymphoma and leukemia in children and adolescents B-NHL 2013 - Behandlungsprotokoll der NHL-BF... not-yet-due
Reported results 2013-004616-21 A 32-week, monocentric, exploratory, single arm study to assess immune function and MRI disease activity in patients with relapsing remitting multiple sclerosis (RRMS) transferred from previous treatm... 2016-02-12 due-trials
Reported results 2014-000709-10 Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential Alemtuzumab in der autoimmunen, entzündlichen Neurodegeneration: Wirkmechanismen und Neu... 2020-11-02 due-trials
Reported results 2014-003022-40 Comparison of the bacterial microbiota in the skin and gut of psoriasis patients before and after sytemic treatment with adalimumab and ustekinumab or cyclosporin Vergleichende Untersuchung der bak... 2017-09-11 due-trials
Reported results 2014-003481-25 A 24-week, multicenter, exploratory, two arm study to assess the effect of Dimethyl fumarate on Immune-Modulatory Action on T cells in patients with relapsing remitting Multiple Sclerosis Eine 24-w... 2018-05-07 due-trials
Reported results 2014-004854-33 Regional citrate versus systemic heparin anticoagulation for continuous renal replacement therapy in critically ill patients with acute kidney injury (RICH-Trial). Regionale Citrat- versus systemis... 2020-01-03 due-trials
Ongoing 2014-005669-54 Clinical safety study on 5-Aminolevulinic acid (5-ALA) in children and adolescents with supratentorial brain tumours Klinisch veiligheidsonderzoek naar 5-Aminolevulinic acid (5-ALA) bij kinderen en... not-yet-due
Ongoing 2015-002727-25 Controlled clinical trial to evaluate the safety and efficacy of stereotactical photodynamic therapy with 5-aminolevulinic acid (Gliolan®) in recurrent glioblastoma Klinisch kontrollierte Studie zu... not-yet-due
Ongoing 2017-001691-39 LBL 2018 - International cooperative treatment protocol for children and adolescents with lymphoblastic lymphoma not-yet-due
Completed, report not yet due 2017-003256-22 Ibrutinib and Standard Immuno-Chemotherapy (R-CHOEP-14) In Younger, High-Risk Patients with Diffuse Large B-Cell Lymphoma Ibrutinib und Standard-Immunochemotherapie (R-CHOEP-14) in jungen Hochrisi... 2023-12-23 not-yet-due
Ongoing 2018-003560-31 A prospective multicenter phase 2 study of copanlisib in combination with rituximab and CHOP chemotherapy (COPA-R-CHOP) in patients with previously untreated diffuse large B-cell lymphoma (DLBCL) ... not-yet-due
Ongoing 2018-004329-10 A Randomized, open-label, Phase 2 Study of Adjuvant Apalutamide or Standard of Care in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy Randomisi... not-yet-due
Other 2018-004557-24 Clarifying the mechanism of action of cladribine in relapsing multiple sclerosis not-yet-due
Ongoing, reported early 2021-003088-87 Biomarker-guided implementation of angiotensin-II (AT-II) to reduce the occurrence of kidney damage after cardiac surgery Biomarker-gesteuerter Einsatz von Angiotensin II zur Verringerung des Auft... not-yet-due
Exempt 2021-004631-92 Phase I/II dose escalation trial of radiodynamic therapy (RDT) with 5-Aminolevulinic acid in patients with first recurrence of glioblastoma Eine Phase I/II-Dosis-Eskalations-Studie zur Radiodynamis... not-yet-due